Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment
| Autor: | Yu-Chun Yen, Jyh Ming Chow, Chia Lun Chang, Wei Cheng Lin, Yin Chun Chang, Han Lin Hsu, Jer Hwa Chang, Kevin Sheng Po Yuan, Alexander T.H. Wu, Szu Yuan Wu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Lung Neoplasms medicine.drug_class Adenocarcinoma of Lung Antineoplastic Agents Afatinib Tyrosine-kinase inhibitor Cohort Studies Erlotinib Hydrochloride 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Epidermal growth factor receptor Stage (cooking) Protein Kinase Inhibitors Aged Neoplasm Staging Proportional Hazards Models Lung biology business.industry Proportional hazards model Hazard ratio Gefitinib Hematology Middle Aged respiratory tract diseases ErbB Receptors 030104 developmental biology medicine.anatomical_structure Tumor progression 030220 oncology & carcinogenesis Mutation Cohort biology.protein Female business |
| Zdroj: | Radiotherapy and Oncology. 129:52-60 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2018.03.007 |
| Popis: | Purpose Large-scale, prospective, randomized studies of the efficacy of thoracic radiotherapy (RT) in patients with unresectable stage IIIB–IV epidermal growth factor receptor (EGFR)-mutant lung adenocarcinomas who received and responded to EGFR tyrosine kinase inhibitor (TKI) treatment are not currently available. Therefore, we designed a propensity score-matched, nationwide, population-based, cohort study for estimating the effects of thoracic RT on patients with EGFR-mutant lung adenocarcinomas. Patients and methods We analyzed patients with unresectable stage IIIB–IV EGFR mutant lung adenocarcinomas and categorized them into two groups according to treatment modality and compared their outcomes; groups 1 and 2 consisted of patients who received EGFR TKI treatment alone until tumor progression and those who received and responded to EGFR TKI treatment and subsequently received thoracic RT for lung tumors, respectively. The patients in groups 2 and 1 were matched at a ratio of 1:4. Results The matching process yielded a final cohort of 1475 patients (1180 and 295 patients in groups 1 and 2, respectively) who were eligible for further analysis. According to both univariate and multivariate Cox regression analyses, the adjusted hazard ratios (aHRs) (95% confidence interval [CI]) derived for thoracic RT for lung tumor after EGFR TKI use and tumor response (group 2) compared with EGFR TKI treatment alone (group 1) was 0.72 (0.60–0.85). Conclusions Thoracic RT might be associated with overall survival in patients with unresectable stage IIIB–IV EGFR-mutant lung adenocarcinomas who received and responded to EGFR TKI treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect